MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • The neurosteroid dehydroepiandrosterone sulfate (DHEAS) reverses the dopaminergic deficiencies in mild hepatic encephalopathy: A possible therapeutic issue for the management of parkinsonism in cirrhotic patients

    O. El Hiba, H. Gamrani (Marrakesh, Morocco)

  • The NIC-PD-study –Baseline data of a randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson’s disease in Germany and the USA

    W.H. Oertel, C. Brittinger, C. Kamp, K. Balthasar, K. Articus, M. Brinkman, C. Venuto, H. Mueller, M.M. Unger, K.M. Eggert, D. Vadasz, K. Kieburtz, J. Boyd (Marburg, Germany)

  • The non-motor side of the honey-moon period of Parkinson’s disease

    R. Erro, M. Picillo, C. Vitale, M. Amboni, M. Moccia, M.T. Pellecchia, P. Barone (London, United Kingdom)

  • The non-motors symptoms in Parkinson’s disease patients with freezing of gait

    H.C. Huang, M.K. Lu, C.H. Tsai (Taichung, Taiwan)

  • The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination

    J. Ellmen, J. Tuunainen, A. Holopainen, T. Sarapohja, M. Scheinin (Turku, Finland)

  • The nucleocytoplasmic transport of ataxin-3 as pathogenic mechanism in spinocerebellar ataxia type 3

    T. Schmidt, A. Sowa, I.M. Martins, M. Abedi, Z. Wang, J. Schmidt, H. Tricoire, O. Riess (Tübingen, Germany)

  • The Parkinson progression marker initiative (PPMI) – Developing a comprehensive longitudinal biomarker dataset

    Parkinson Progression Marker Initiative (New Haven, CT, USA)

  • The patient’s perspective: The effect of dopamine on Parkinson symptoms

    H. Zach, M.F. Dirkx, J.W. Pasman, B.R. Bloem, R.C. Helmich (Vienna, Austria)

  • The patterns of olfactory function in Parksinson’s disease patients with mild cognitive impairment

    J.W. Park, H.K. Yoon, M.H. Park, D.Y. Kwon (Ansan, Korea)

  • The phenotypic and genetic features of myoclonus-dystonia in six Saudi Arabian kindreds

    S.A. Bohlega, A. Aldakheel, T. Alkhairallah, A. Alkhani, M. Almuhaizea, F. Alotaibi (Riyadh, Saudi Arabia)

  • « Previous Page
  • 1
  • …
  • 187
  • 188
  • 189
  • 190
  • 191
  • …
  • 207
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Life expectancy with and without Parkinson’s disease in the general population
    • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
    • An atypical and interesting feature of Parkinson´s disease
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley